secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001649094-25-000027
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte reports Q4 2024 net loss of $137.1M; cash $3.13B; VAX-31 Phase 3 on track for mid-2025
--------------------------------------------------------------------------------

- Net loss Q4 2024: $137.1M; full year 2024: $463.9M vs $402.3M in 2023.
- Cash, cash equivalents and investments: $3.13B at Dec 31, 2024, up from $1.24B a year ago.
- R&D expenses $133.6M in Q4; $476.6M for full year on increased PCV program activities.
- VAX-31 adult Phase 3 pivotal study expected to start by mid-2025 with topline data in 2026.
- VAX-24 infant Phase 2 primary immunization topline data expected by end of Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000164909425000027/0001649094-25-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000164909425000027/pcvx-20250225.htm
  HTML page:      https://secwatch.observer/filing/0001649094-25-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer